Publication List

Published papers in peer-reviewed journals

1. Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, Wang LY, You SL, Chen WJ,
   and Chen CJ*. Hepatitis C virus seromarkers and subsequent risk of hepatocellular
   carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol, 2010;
   28: 4587-93. (IF=26.3)
2. Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, Liu CJ, You SL, Chen WJ, and Chen CJ*. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke, 2010;
   41:2894-900. (IF=6.2)
3. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, You SL, Iloeje UH, and Chen CJ*.
   Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a
   community-based follow-up study. Gastroenterology, 2010; 139: 474-82. (IF=20.7)
4. Wang CH*, Chen CJ, Lee MH, Yang HI, and Hsaio CK. Chronic hepatitis B infection and
   risks of atherosclerosis-related mortality: a 17-year follow-up study based on 22,472
   residents in Taiwan. Atherosclerosis, 2010; 211: 624-9. (IF=4.5)
5. Lee MH, Yang HI, Jen CL, Yeh SH, Liu CJ, You SL, Sun CA, Wang LY, Chen WJ, and Chen
   CJ*. Community and personal risk factors for HCV infection: a survey of 23,820 residents in
   Taiwan. Gut, 2011; 60: 688-94. (IF=17.0)
6. Lee MH, Yang HI, Wang CH, Chen CJ*. Response to Letter by Lin et al Regarding article,
   “Hepatitis C virus infection and increased risk of cerebrovascular disease”. Stroke,
   2011;42:E390-E1. (IF=6.2)
7. Chen CJ* and Lee MH. Early diagnosis of hepatocellular carcinoma by multiple
   microRNAs: validity, efficacy and cost-effectiveness. J Clin Oncol, 2011; 29; 4745-7.
   (IF=26.3)
8. Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, Iloeje UH, Chen CJ*. Lifetime risk and
   sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J
   Clin Oncol, 2011;29:3643-50. (IF=26.3)
9. Yang HI, Hung HL, Lee MH, Liu J, Jen CL, Su J, Wang LY, Lu SN, You SL, Iloeje UH,
   Chen CJ*. Incidence and determinants of spontaneous seroclearance of HB e antigen and
   DNA in patients with chronic hepatitis B. Clin Gastroenterol Hepatol, 2011; 10: 527-34.
   (IF=7.7)
10. Yang HI, Lee MH, Chen CJ*. Prediction of hepatocellular carcinoma risk in chronic
    hepatitis B and C: review of findings in R.E.V.E.A.L.-HBV/HCV study. J Clin Hepatol,
    2011; 27:357-62. (in Chinese)
11. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ*.
    Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic
    diseases : a community-based long-term prospective study. J Infect Dis, 2012 ; 206 : 469-77. (IF=5.3, citations=350 to Nov, 2018)
12. Lee MH, Yang HI, Chen CJ*. Long-term health outcomes of chronic hepatitis C patients: A
    review of findings from REVEAL-HCV cohort study. Biomedicine, 2012; 2 (3): 99-107.
13. Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC*. Fifteen-year population attributable
    fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in
    11,801 men in Taiwan. PLoS One, 2012; 7 (4): e34779. (IF=2.8)
14. Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, You SL, Wang LY,
    Chen CJ*. Prediction model of long-term liver cirrhosis and hepatocellular carcinoma risk in
    chronic hepatitis B patients: risk scoresintegrating host and hepatitis B virus profiles.
    Hepatology, 2013;58 (2):546-554. (IF=14.1)
15. Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao
    CK, Yang HI, Chen CJ*. A predictive scoring system for the seroclearance of HBsAg in
    HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol,
    2013;58 (5): 853-60. (IF=14.9)
16. Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, Lu SN, Liu J, Chen CJ*.
    Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic
    hepatitis B patients. PLoS One, 2013; 8 (4) : e61448. (IF=2.8)
17. Loomba R, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, Iloeje UH, Su J, You SL, Brenner D,
    Chen CJ*. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B
    virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol,
    2013; 11 (12): 1636-1645. (IF=7.7)
18. McEwan P*, Ward T, Chen CJ, Lee MH, Yang HI, Kim R, L’Italien G, Yuan Y. Estimating
    the incidence and prevalence of chronic hepatitis C infection in Taiwan using back
    projection. Value in Health, 2013; 3: 5-11. (IF=5.5)
19. Lee MH, Lu SN, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L’Italien G, Chen CJ.
    Development and validation of a clinical scoring system for predicting risk of hepatocellular
    carcinoma in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One,
    2014: e94760. (IF=2.8)
20. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, L’Italien G, Chen CJ*, Yuan Y.
    Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. International Journal of Cancer, 2014; 135: 1119-1126. (IF=7.4)
21. Lee MH, Yang HI, Yuan Y, L’Italien G, Chen CJ*. Epidemiology and natural history of
    hepatitis C virus infection. World Journal of Gastroenterology, 2014; 20: 9270-9280.
    (IF=3.3)
22. Yang HI, Lee MH, Liu J, Chen CJ*. Risk calculators for hepatocellular carcinoma in patients
    affected with chronic hepatitis B. World Journal of Gastroenterology, 2014; 20: 6244-6251.
    (IF=3.3)
23. Liu J, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, Wang LY, You SL, Hsiao
    CK,Chen CJ*. Distinct seromarkers predict different milestones of chronic hepatitis B
    progression. Hepatology, 2014 ; 60 (1) : 77-86. (IF=14.1)
24. Chen CJ*, Hsu WL, Yang HI, Lee MH, Chen HC, Chien YC, You SL. Epidemiology of virus
    infection and human cancer. Recent Results Cancer Research, 2014; 193: 11-32.
25. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla-Utermann R, Wang LY, You SL, Hsiao CK,
    Chen PJ, Chen CJ*. Spontaneous seroclearance of hepatitis B seromarkers and subsequent
    risk of hepatocellular carcinoma. Gut, 2014; 63 (10): 1648-57. (IF=17.0)
26. Hsu CE, Chiu YC, Tsai SH, Lin TC, Lee MH*, Huang KC. Trochanter stabilising
    plate improves treatment outcomes in AO/OTA 31-A2 intertrochanteric fractures with
    critical thin femoral lateral walls. Injury, 2015; 46 (6): 1047-53. (IF=2.1)
27. Chiang CJ, Yang YW, Chen JD, You SL, Yang HI, Lee MH, Lai MS, Chen CJ*. Significant
    reduction in end-stage liver diseases burden through national viral hepatitis therapy program
    in Taiwan. Hepatology, 2015; 61 (4): 1154-62. (IF=14.1)
28. Liu J, Tseng TC, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, Wang LY, You SL,
    Chen PJ, Chen CJ*, Kao JH. Predicting hepatitis B virus (HBV) surface antigen
    seroclearance in HBV e antigen-negative patients with chronic hepatitis B: external
    validation of a scoring system. J Infect Dis, 2015; 211 (10): 1566-73. (IF=5.3)
29. Chen CJ*, Lee MH, Liu J, Yang HI. Hepatocellular carcinoma risk scores: ready to use in
    2015? Hepatic Oncology, 2015; 2 (1): 1-4.
30. Lee MH, Yang HI, Lu SN, Lin YJ, Jen CL, Wong KH, Chan SY, Chen LC, Wang LY, Yuan Y, L’Italien G, Chen CJ. Polymorphisms near the IFNL3 gene associated with HCV RNA
    spontaneous clearance and hepatocellular carcinoma risk. Scientific Reports, 2015; 5: 17030. (IF=4.1) (NSC 102-2314-B-010-057-MY2)
31. Chen HY, Yu SL, Ho BC, Su KY, Hsu YC, Chang CS, Li YC, Yang SY, Hsu PY, Ho H, Chan
    YH, Chen CY, Yang HI, Hsu CP, Yang TY, Chen KC, Hsu KH, Tseng JS, Hsia JY, Chuang
    CY, Yuan S, Lee MH, Liu CH, Wu GI, Hsiung CA, Chen YM, Wang CL, Huang MS, Yu CJ,
    Chen KY, Su WC, Chen HW, Chen J JW, Chen CJ, Chang GC, Yang PC, Li KC*. R331W
    missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with
    medical actionability. J Clin Oncol, 2015; 33 (20): 2303-10. (IF=26.3)
32. Chien J, Liu J, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, You SL, Yang HI,
    Chen CJ*. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients
    with newly developed cirrhosis. J Gastroenterol Hepatol, 2016; 31 (12): 1971-1977.
    (IF=3.5)
33. Liu J, Yang HI, Lee MH, Jen CL, Hu HH, Lu SN, Wang LY, You SL, Huang YT, Chen CJ*.
    Alcohol drinking mediates the association between polymorphisms of ADH1B and ALDH2
    and hepatitis B related hepatocellular carcinoma. Cancer Epidemiology Biomarkers and
    Prevention, 2016; 25 (4): 693-9. (IF=4.6)
34. Hwang YT*, Freeman JR, Yang HI, Liu J, Lee MH, Chen CJ. Mediation effect of hepatitis B
    and C on mortality. European Journal of Epidemiology, 2016; 31 (6): 625-33. (IF=7.0)
35. Hu HH, Liu J, Lin YL, Luo WS, Chu YJ, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY,
    You SL, Yang HI*, Chen CJ. The rs2296651 (S267F) variant on NTCP (SLC10A1) is
    inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular
    carcinoma in patients with chronic hepatitis B. Gut, 2016; 65 (9): 1514-21. (IF=17.0)
36. Yang HI, Tseng TC, Liu J, Lee MH, Liu CJ, Su TH, Batrla-Utermann R, Chan HL, Kao JH,
    Chen CJ*. Incorporating serum levels of hepatitis B surface antigen or omitting level of
    hepatitis B virus DNA does not affect calculation of risk for hepatocellular carcinoma in
    patients without cirrhosis. Clin Gastroenterol Hepatol, 2016;14 (3):461-468. (IF=7.7)
37. Hwang YT*, Yang HI, Liu J, Lee MH, Freeman J, Chen CJ. Mediation analysis of hepatitis
    B and C in relation to hepatocellular carcinoma risk. Epidemiology, 2016; 27 (1): 14-20.
    (IF=5.0)
38. Younossi ZM, Stepanova M, Chan H LY, Lee MH, Yu ML, Dan YY, Choi MS, Chan HL. Patient-reported outcomes in Asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine, 2016; 95 (9): e2702. (IF=2.0) 39. Liu J, Yang HI, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, You SL, Chen CJ.
    Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low
    risk of disease progression. Hepatology, 2016; 64 (2): 381-9. (IF=14.1)
39. Rao HY, Li H, Chen H, Shang J, Xie Q, Gao ZL, Li J, Sun YT, Jiang JN, Wang L, Zhao LF,
    Zhang LJ, Yang WB, Niu JQ, Gong ZJ, Gong GZ, Yang RF, Lee MH, Wei L*. Real world
    treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an
    interim analysis from the CCgenos study. J Gastroenterol Hepatol, 2016; 32 (1): 244-252.
    (IF=3.5)
40. Hsu CE, Huang KC, Lin TC, Tong KM, Lee MH, Chiu YC. Integrated risk scoring model
    for predicting dynamic hip screw treatment outcome of intertrochanteric fracture. Injury,
    2016; 47 (11): 2501-2506. (IF=2.1)
41. Lin YJ, Shaw TW G, Yang HI, Lu SN, Jen CL, Wang LY, Wong KH, Chan SY, Yuan Y,
    L’Italien G, Chen CJ, Lee MH*. Chronic hepatitis C virus infection and the risk for diabetes:
    a community-based prospective study. Liver International, 2017; 37 (2): 179-186. (IF=4.5)
    (NSC 102-2314-B-010-057-MY2 and MOST 104-2628-B-010-001-MY3)
42. Chen MH, Chen MH, Liu CH, Tsai CY, Huang DF, Lin HY, Lee MH, Huang YH.
    Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment.
    J Infect Dis, 2017; 215 (4): 566-573. (IF=5.3)
43. Huang CF, Yeh ML, Huang CI, Lin YJ, Tsai PC, Lin ZY, Chan SY, Chen SC, Yang HI,
    Huang JF, Lu SN, Dai CY, Jen CL, Y Yuan, G L’Italien, Wang LY, Lee MH, Yu ML,
    Chuang WL, Chen CJ. Risk of hepatitis C virus related hepatocellular carcinoma between
    subjects with spontaneous and treatment-induced viral clearance. Oncotarget, 2017; 8 (27):
    43925-43933. (IF=5.2)
44. Lee MH, Hsiao TI, Subramaniam SR, Le AK, Vu VD, Trinh HN, Zhang J, Jin M, Wong
    VWS, Wong GLH, Nguyen MH. HCV genotype 6 increased the risk for hepatocellular
    carcinoma among Asian patients with liver cirrhosis. American Journal of
    Gastroenterology, 2017; 112 (7): 1111-1119. (IF=10.2) (MOST 104-2628-B-010-001-MY3
    and MOST 105-2628-B-010-003-MY4)
45. Lai TH, Lee MH, Yang, HI, You SL, Lu SN, Wang LY, Yuan Y, L’Italien G, Chien KL, Chen
    CJ. Hepatitis C Viral Load, Genotype and Increased Risk of Developing End-Stage Renal
    Disease: the REVEAL-HCV Study. Hepatology, 2017; 66 (3): 784-793. (IF=14.1) 47. Lee MH*, Huang CF, Lai HC, Lin CY, Dai CY, Liu CJ, Wang JH, Huang JF, Su WP, Yang
    HC, Kee KM, Yeh ML, Chuang PH, Hsu SJ, Huang CI, Kao JT, Chen CC, Chen SH, Jeng
    WJ, Yang HI, Yuan Y, Lu SN, Sheen IS, Liu CH, Peng CY, Kao JH, Yu ML, Chuang WL,
    Chen CJ. Clinical efficacy and post-treatment seromarkers associated with the risk of
    hepatocellular carcinoma among chronic hepatitis C patients. Scientific Reports, 2017; 7 (1):
46. (IF=4.1) (MOST 104-2628-B-010-001-MY3 and MOST 105-2628-B-010-003-MY4)
47. Lai TH, Lee MH, Yang HI, You SL, Lu SN, Wang LY, Yuan Y, L’Italien G, Chien KL, Chen
    CJ. High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney
    disease. Kidney International, 2017; 92 (3): 703-709. (IF=8.4)
48. Chu YJ, Yang HI, Wu HC, Liu J, Wang LY, Lu SN, Lee MH, Jen CL, You SL, Santella RM,
    Chen CJ. Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma
    in chronic hepatitis B virus carriers. International Journal of Cancer, 2017; 141 (4): 711-
49. (IF=7.4)
50. Chen CH, Lee CM, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Wang JH, Lee MH,
    Peng CY. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic
    hepatitis B treated with entecavir. Oncotarget, 2017; 8 (54): 92431-92441. (IF=5.2)
51. Liu J, Hu HH, Lee MH, Korenaga M, Jen CL, Batrla-Utermann R, Lu SN, Wang LY,
    Mizokami M, Chen CJ, Yang HI. Serum levels of M2BPGi as short-term predictors of
    hepatocellular carcinoma in chronic hepatitis B. Scientific Reports, 2017; 7 (1): 14352.
    (IF=4.1)
52. Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom
    R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S, Abdelmageed MK, Adda
    D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Kaabi S, Al Naamani K, Al Qamish
    J, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo
    W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright
    B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen DS, Chen PJ, Chien RN, Chuang
    WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Gamkrelidze I, Garcia
    V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig
    O, Hamoudi W, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kamel
    Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao
    WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Malu AO, Mateva
    L, Mitova R, Morović M, Murphy K, Mustapha B, Nde H, Nersesov A, Ngige E, Njoya O, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Phillips
    RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Redae B, Reic T, Rinke de Wit T, Rios
    C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Simonova M, Su TH, Sultan
    K, Tan SS, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi
    R, Wani HU, Wong VWS, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Razavi-Shearer
    K. Historical epidemiology of hepatitis C virus in select countries: Volume 4. Journal of
    Viral Hepatitis, 2017; Suppl 2:8-24. (IF=4.2)
53. Chan HLY, Chen CJ, Omede O, Al Qamish J, Al Naamani K, Bane A, Tan SS, Simonova
    M, Cardenas I, Derbala M, Akin O, Phillips RO, Abdelmageed MK, Abdulla M, Adda D, Al
    Baqali A, Al Dweik N, Al Ejji K, Al Ghazzawi I, Al Kaabi S, Al Sadadi M, Al Salman
    J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome
    F, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Chen DS, Chen PJ, Chien
    RN, Chuang WL, Cuellar D, Elbardiny AA, Estes C, Farag E, Fung J, Gamkrelidze I, Garcia
    V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig
    O, Hamoudi W, Himatt SM, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John
    AK, Kaliaskarova KS, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova
    A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić
    B, Maaroufi A, Malu AO, Mateva L, Mitova R, Mohamed R, Morović M, Murphy
    K, Mustapha B, Nersesov A, Ngige E, Njouom R, Njoya O, Nonković D, Obekpa S, Oguche
    S, Okolo EE, Omuemu C, Ondoa P, Opare-Sem O, Owusu-Ofori S, Prokopenko YN, Razavi
    H, Razavi-Shearer D, Razavi-Shearer K, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins
    S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Su TH, Sultan K, Tchernev K, Tsang
    OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Vince A, Wani HU, Wong
    VWS, Workneh A, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Nde H. The present
    and future disease burden of hepatitis C virus infections with today’s treatment paradigm:
    Volume 4. Journal of Viral Hepatitis, 2017; Suppl 2: 25-43. (IF=4.2)
54. Chen DS, Hamoudi W, Mustapha B, Layden J, Nersesov A, Reic T, Garcia V, Rios
    C, Mateva L, Njoya O, Al-Busafi SA, Abdelmageed MK, Abdulla M, Adda D, Akin O, Al
    Baqali A, Al Dweik N, Al Ejji K, Al Ghazzawi I, Al Kaabi S, Al Naamani K, Al Qamish
    J, Al Sadadi M, Al Salman J, AlBadri M, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike
    C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas
    I, Chan HLY, Chen CJ, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny
    AA, Estes C, Farag E, Fung J, Gamkrelidze I, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Himatt SM, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis
    R, Jelev D, John AK, Kaliaskarova KS, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri
    I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Lee MH, Lesi O, Li M, Lo A, Loo
    CK, Lukšić B, Maaroufi A, Malu AO, Mitova R, Mohamed R, Morović M, Murphy K, Nde
    H, Ngige E, Njouom R, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu
    C, Ondoa P, Opare-Sem O, Owusu-Ofori S, Phillips RO, Prokopenko YN, Razavi H, RazaviShearer D, Razavi-Shearer K, Redae B, Rinke de Wit T, Robbins S, Roberts LR, Sanad
    SJ, Sharma M, Simonova M, Su TH50, Sultan K, Tan SS, Tchernev K, Tsang OTY, Tsang
    S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Vince A, Wani HU, Wong VWS, Workneh
    A, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Schmelzer JD. Strategies to manage
    hepatitis C virus infection disease burden: Volume 4. Journal of Viral Hepatitis, 2017;
    Suppl 2:44-63. (IF=4.2)
55. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of
    hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol, 2017;
    2 (3):161-176.
56. Lee PC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lee MH, Hou MC, Lee FY, Lin HC,
    Huang YH. Validation of the ALBI grade-based integrated model as a predictor for
    sorafenib-failed hepatocellular carcinoma. Liver International, 2018; 38 (2): 321-330.
    (IF=4.5)
57. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis
    B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol, 2018; 3 (6):
    383-403.
58. Lee MH*, Huang YH, Chen HY, Khor C SS, Chang YH, Lin YJ, Jen CL, Lu SN, Yang HI,
    Nishida N, Sugiyama M, Mizokami M, Yuan Y, L’Italien G, Tokunaga K, Chen CJ. Human
    leukocyte antigen variants and risk of hepatocellular carcinoma modified by HCV
    genotypes: a genome-wide association study. Hepatology, 2018; 67 (2): 651-661. (IF=14.1)
    (MOST 104-2628-B-010-001-MY3 and MOST 105-2628-B-010-003-MY4)
59. Younossi ZM, Stepanova M, Chan H LY, Lee MH, Yu ML, Dan YY, Choi MS, Chan HL. Impact of Ledipasvir/Sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. Journal of Viral Hepatitis, 2018; 25 (3): 228-235. (IF=4.2)
60. Chen MH, Lee MH, Liao HT, Chen WS, Lai CC, Tasi CY. Health-related quality of life
    outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering
    biologic treatment. Clinical Rheumatology, 2018; 37 (2): 429-438. (IF=2.1)
61. Chu YJ, Yang HI, Wu HC, Lee MH, Liu J, Wang LY, Lu SN, Jen CL, You SL, Santella RM,
    Chen CJ*. Aflatoxin B1 exposure increases the risk of hepatocellular carcinoma associated
    with hepatitis C virus infection or alcohol consumption. European Journal of Cancer,
    2018; 94: 37-46. (IF=7.2)
62. Lee MH*. Risk of hepatocellular carcinoma for patients treated with direct-acting antivirals:
    Steps after hepatitis C virus eradication to achieve elimination. Translational
    Gastroenterology and Hepatology, 2018; 3: 15.
63. Kutsenko A, Le AK, Lee MH, Lin YJ, Nguyen P, Trinh Sm Dang H, Nguyen MH*. Higher
    risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic
    risk factors. Scientific Reports, 2018; 8: 7164. (IF=4.1)
64. Chen VL, Yeh ML, Le AK, Jun M, Saeed WK, Yang JD, Huang CF, Lee HY, Tsai PC, Lee
    MH, Giama N, Kim NG, Nguyen PP, Dang H, Ali HA, Zhang N, Huang JF, Dai CY, Chuang
    WL, Roberts LR, Jun DW, Lim YS, Yu ML, Nguyen MH*. Antiviral therapy is associated
    with improved survival but underutilized in patients with hepatitis B virus-related
    hepatocellular carcinoma: real-world east and west experience. Aliment Pharmacol Ther,
    2018: 48 (1): 44-54. (IF=7.4)
65. Lin YJ, Chang CL, Chen LC, Hu HH, Liu J, Korenaga M, Huang YH, Jen CL, Su CY,
    Nishida N, Sugiyama M, Lu SN, Wang LY, Yuan Y, L’Italien G, Yang HI, Mizokami M,
    Chen CJ, Lee MH*. A Glycomarker for short-term prediction of hepatocellular carcinoma: A
    longitudinal study with serial measurements. Clinical and Translational Gastroenterology,
    2018: 9 (9): 183. (IF=4.6) (MOST 104-2628-B-010-001-MY3 and MOST 105-2628-B010-003-MY4)
66. Hu HH, Liu J, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, Quan Y, Xia NS, Chen CJ,
    Chen PJ, Yang HI*. Level of hepatitis B (HB) core antibody associates with seroclearance of
    HBV DNA and HB surface antigen in HB e antigen-seronegative patients. Clin
    Gastroenterol Hepatol, 2019: 17 (1): 172-181. (IF=7.7)
67. Nguyen MH*, Yang HI, Le A, Henry L, Nguyen N, Lee MH, Zhang J, Wong C, Wong C,
    Trinh H. Reduced incidence of hepatocellular carcinoma with tenofovir in chronic hepatitis B patients with and without cirrhosis – a propensity score matched study. J Infect Dis, 2019:
    219 (1): 10-18. (IF=5.3)
68. Estevez J, Yang JD, Leong J, Nguyen P, Giama NH, Zhang N, Ali HA, Lee MH, Cheung R,
    Roberts L, Schwatz M, Nguyen MH*. Clinical features associated with survival outcome in
    African American patients with hepatocellular carcinoma. American Journal of
    Gastroenterology, 2019: 114 (1): 80-88. (IF=10.2)
69. Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee
    MH, Chen CH, Peng CY*. Stratification of hepatocellular carcinoma risk through modified
    FIB-4 index in chronic hepatitis B patients on entecavir therapy. J Gastroenterol Hepatol,
    2019; 34 (2): 442-449. (IF=3.5)
70. Trinh S, Le AK, Chang ET, Hoang J, Jeong D, Chung M, Lee MH, Wang U, Henry L,
    Cheung R, Nguyen MH*. Changes in renal function in patients with chronic HBV infection
    treated with tenofovir disoproxil fumarate vs entecavir. Clin Gastroenterol Hepatol, 2019;
    17 (5): 948-956. (IF=7.7)
71. Liu J, Hu HH, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, Yuan Q, Xia NS, Sugiyama
    M, Nishida N, Mizokami M, Chen CJ, Chen PJ, Yang HI*. Association between high levels
    of hepatitis B core antibody and seroclearance of hepatitis B e antigen in individuals with
    chronic hepatitis B virus infection. Clin Gastroenterol Hepatol, 2019; 17 (7): 1413-1415.
72. Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee
    DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda
    S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai
    CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka
    Y, Yu ML, Nguyen MH*; REAL-C Investigators. Direct-acting antivirals in East Asian
    hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatology
    International, 2019; 13 (5): 587-598.
73. Tsai DH, Lee MH, Chen DS, Liaw YF, PC Yang, Huang YH, Chen CJ*. Taiwan’s healthcare system and administration are independent of China. Lancet, 2019; 394 (10208): 1516.
    DOI:https://doi.org/10.1016/S0140-6736(19)31622-8
74. Lee MH, Gao YT, Huang YH, McGee EE, Lam T, Wang B, Shen MC, Rashid A, Pfeiffer RM, Hsing AW, Koshiol J. A Metallomic approach to assess associations of serum metal levels with gallstones and gallbladder cancer. Hepatology, 2020; 71 (3): 917-28. (MOST
    107-2314-B-010-004-MY2 and MOST 107-2918-I-010-004)
75. Liu CH, Lee MH, Lin JW, Liu CJ, Su TH, Tseng TC, Chen PJ, Chen DS, Kao JH*.
    Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free
    direct acting antivirals. Journal of Hepatology, 2020; 72 (5): 839-846.
76. Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S,
    Wong G, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH,
    Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai
    CY, Huang JF, Yang HI, Lee MH, Jung Jun M, Kao JH, Eguchi Y, Ueno Y, Tamori
    A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH*; REAL-C Investigators, Ahn SB, Azuma
    K, Dohmen K, Yoon Jeong J, Jung JH, Kajiwara E, Kato M, Kawano A, Koyanagi T, Ooho
    A, Park SH, Satoh T, Shimoda S, Song DS, Takahashi K, Yeh ML, Yoon EL. HCV cure rates
    are reduced in patients with active but not inactive hepatocellular carcinoma – a practice
    implication. Clin Infect Dis, 2020; 71 (11): 2840-2848.
77. Chien LH, Chen CH, Chen TY, Chang GCm Tsai YH, Hsiao CF, Chen KY, Su WC, Wang
    WC, Huang MS, Chen YM, Chen CY, Liang SK, Chen CY, Wang CL, Lee MH, Chung RH,
    Tsai FY, Hu JW, Katki HA, Chatterjee N, Chanock SJ, Rothman N, Lan Q, Yang PC, Chen
    CJ, Chang IS, Hsiung CA*. Predicting lung cancer occurrence in never-smoking females in
    Asia: TNSF-SQ, a prediction model. Cancer Epidemiol Biomarkers Prev, 2020; 29 (2):
    452-459.
78. Young SH, Chau GY, Lee IC, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Lee
    MH, Huang YH. Aspirin is associated with low recurrent risk in hepatitis B virus-related
    hepatocellular carcinoma patients after curative resection. Journal of the Formosan
    Medical Association, 2020; 119 (1): 218-229.
79. Huang C, Chen SP, Huang YH, Chen HY, Wang YF, Lee MH, Wang SJ. HLA class I
    alleles are associated with clinic-based migraine and increased risk of chronic migraine and
    medication overuse. Cephalalgia, 2020; 40 (5): 493-502.
80. Huang YH, Khor SS, Zhen X, Chen HY, Chang YH, Chu HW, Wu PE, Lin YJ, Liao SF,
    Shen CY, Tokunaga K, Lee MH. A high-resolution HLA imputation system for the
    Taiwanese population: a study of the Taiwan Biobank. The Pharmacogenomoics Journal,
    2020; 20: 695-704.
81. Wu PF, Hang JF, Strong C, Chen SJ, Lin LY, Chen SS, Lai CR, Ku SWW, Lee MH*. Anal
    human papillomavirus and its associations with abnormal anal cytology among men who
    have sex with men. Scientific Reports. 2020; 10: 3165.
82. Huang WY, Tsai CL, Que JY, Lo CH, Lin YJ, Dai YH, Yang JF, Shen PC, Lee MH, Cheng JCH. Development and validation of a nomogram for patients with non-metastatic BCLC
    stage C hepatocellular carcinoma after stereotactic body radiotherapy. Liver Cancer, 2020; 9
    (3): 326-337.
83. Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee
    MH, Chen CH, Peng CY. On-treatment changes in FIB-4 and 1-year FIB-4 values help
    identify patients with chronic hepatitis B receiving entecavir therapy who have the lowest
    risk of hepatocellular carcinoma. Cancers. 2020; 12 (5): 1177.
84. Raghav L, Chang YH, Hsu YC, Li YC, Chen CY, Yang TY, Chen KC, Hsu KH, Tseng JS,
    Chuang CY, Lee MH, Wang CL, Chen HW, Yu SL, Su SF, Yuan SS, Chen JJW, Ho SY, Li
    KC, Yang PC, Chang GC, Chen HY. Landscape of Mitochondria Genome and Clinical
    Outcomes in Stage 1 Lung adenocarcinoma. Cancers. 2020; 12 (3): 755.
85. Jackson SS, Adami HO, Andreotti G, Beane-Freeman LE, Berrington de González A, Buring
    JE, Fraser GE, Freedman ND, Gapstur SM, Gierach G, Giles GG, Grodstein F, Hartge P,
    Jenab M, Kirsh V, Knutsen SF, Lan Q, Larsson SC, Lee IM, Lee MH, Liao LM, Milne RL,
    Monroe KR, Neuhouser ML, O’Brien KM, Petrick JL, Purdue MP, Rohan TE, Sandin S,
    Sandler DP, Sawada N, Shadyab AH, Simon TG, Sinha R, Stolzenberg-Solomon R, Tsugane
    S, Weiderpass E, Wolk A, Yang HI, Zheng W, McGlynn KA, Campbell PT, Koshiol J.
    Associations between reproductive factors and biliary tract cancers in women from the
    Biliary Tract Cancers Pooling Project. J Hepatol. 2020; 73: 863-872.
86. Petrick JL, Florio AA, Koshiol J, Pfeiffer RM, Yang B, Yu K, Chen CJ, Yang HI, Lee MH,
    McGlynn KA. Prediagnostic concentrations of circulating bile acids and hepatocellular
    carcinoma risk: REVEAL-HBV and HCV studies. Int J Cancer. 2020; 147 (10): 2743-2753.
87. Huang YH, Liao SF, Khor, SS, Lin YJ, Chen HY, Chang YH, Huang YH, Lu SN, Lee HW,
    Ko WY, Huang C, Liu PC, Chen YJ, Wu PF, Chu HW, Wu PE, Tokunaga K, Shen CY, Lee
    MH. Large-scale genome-wide association study identifies HLA class II variants associated with chronic HBV infection: a study from Taiwan Biobank. Aliment Pharmacol Ther. 2020; 52 (4): 682-691. 88.
88. Lee MH and Huang YH. Editorial: genome-wide association for developing chronic
    hepatitis B-author’s reply. Aliment Pharmacol Ther. 2020; 52 (6): 1085-1086.
89. Lee MH*, Huang YH, Coghill AE, Liu Z, Yu KJ, Hsu WL, Chien YC, Wang CP, Chen TC,
    Chen CJ, Hildesheim A. Epstein-Barr virus (EBV) based nasopharyngeal carcinoma (NPC)
    risk prediction scores are elevated in NPC multiplex family members compared to the
    general population in Taiwan. J Infect Dis, 2021; 223 (3): 441-444
90. Chen CJ, You SL, Hsu WL, Yang HI, Lee MH, Chen HC, Chen YY, Liu J, Hu HH, Lin YJ,
    Chu YJ, Huang YT, Chiang CJ, Chien YC. Epidemiology of virus infection and human
    cancer. Recent Results Cancer Res. 2021; 217: 13-45.
91. Chen CY, Huang CF, Cheng PN, Tseng KC, Lo CC, Kuo HT, Huang YH, Tai CM, Peng CY,
    Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF,
    Yang CC, Hu JT, Lin CW, Chen CT, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee
    TH, Chen GY, Wang SJ, Chang CC, Mo LR, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao
    CN, Tsai PC, Liu CH, Lee MH, Liu CJ, Dai CY, Kao JH, Chuang WL, Lin HC, Yu ML.
    Factors with DAAs treatment failure for chronic hepatitis C-a real-world nationwide HCV
    Registry Program (TACR) in Taiwan. Liver International. 2021; 41: 1265-1277.
92. Lo YH, Cheng HC, Wang HY, Peng CW, Chen CY, Lin KP, Kang ML, Hsiung CN, Chen
    CH, Chu HW, Shen CY, Lin CF, Lee MH, Liu Q, Satta Y, Lin CJ, Lin M, Chaw SM, Loo JH,
    Ko WY. Detecting genetic ancestry and adaptation in the Taiwanese Han people. Molecular
    Biology and Evolution. 2020
93. Liu Z, Derkach A, Yu KJ, Yeager M, Chang YS, ChenCJ, Gyllensten U, Lan Q, Lee MH,
    McKay JD, Rothman N, Yang HI, Hildesheim A, Pfeiffer RM. Patterns of human leukocyte
    antigen class I and class II associations and cancer. Cancer Research. 2021; 81 (4): 1148-1152.
94. Liu Z, Huang CJ, Huang YH, Pan MH, Lee MH, Yu KJ, Pfeiffer RM, Viard M, Yuki Y, Gao
    X, Carrington M, Chen CJ, Hildesheim A, Yang HI. HLA zygosity increases risk of hepatitis
    B-associated hepatocellular carcinoma. Journal of Infectious Diseases. 2021
95. Liu PC, Chan C, Huang YH, Chen YJ, Liao SF, Lin YJ, Huang C, Lu SN, Jen CL, Wang LY,
    Yang HI, Shen CY, Chen CJ, Lee MH. Genetic variants associated with serum alanine aminotransferase levels among patients with hepatitis C virus infection: a genome-wide association study. J Viral Hepatitis. 2021
96. Liao SF, Koshiol J, Huang YH, Jackson SS, Huang YH, Chan C, Huang C, Liu PC, Chen YJ, Hsieh R, Huang JB, Lu SN, Chen CJ, Shen CY, Lee MH. Postdiagnosis aspirin use
    associated with biliary tract cancer-specific mortality in a large nationwide cohort.
    Hepatology. 2021. DOI:10.1002/hep.31879

Books or Chapters